Q1: 2026-05-05 Earnings Summary
EPS of $0.44 misses by $0.43
| Revenue of $58.82M (10.28% Y/Y) misses by $3.58M
Rigel Pharmaceuticals, Inc. (RIGL) M&A Call May 12, 2026 8:00 AM EDT
Company Participants
Raymond Furey – Executive VP, Chief Compliance Officer, General Counsel & Corporate Secretary
Raul Rodriguez – President, CEO & Director
Lisa Rojkjaer – Executive VP & Chief Medical Officer
Erika Hamilton
David Santos – Executive VP & Chief Commercial Officer
Conference Call Participants
Joseph Pantginis – H.C. Wainwright & Co, LLC, Research Division
Kristen Kluska – Cantor Fitzgerald & Co., Research Division
Yigal Nochomovitz – Citigroup Inc., Research Division
Farzin Haque – Jefferies LLC, Research Division
Ashleigh Acker – Piper Sandler & Co., Research Division
Presentation
Operator
Greetings. Welcome to Rigel Pharmaceutical VEPPANU Licensing Agreement Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce our first speaker, Ray Furey, Rigel’s Executive Vice President, General Counsel and Corporate Secretary. Thank you, Mr. Furey. You may begin.
Raymond Furey
Executive VP, Chief Compliance Officer, General Counsel & Corporate Secretary
Welcome to our conference call to discuss Rigel’s in-licensing of VEPPANU or Vepdegestrant. The press release announcing the transaction was issued earlier this morning and can be viewed along with the slides for this presentation in the News and Events section of Investor Relations site on rigel.com.
As a reminder, during today’s call, we may make forward-looking statements regarding our plans and timing for the regulatory review of the transaction and development and commercialization of VEPPANU. In addition, as noted in the press release issued this morning and here in the presentation, this transaction is subject to customary closing conditions, including review under the Hart-Scott-Rodino Antitrust Improvements Act. The statements made today are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks are identified in the slides and in our most recent annual report on Form 10-K for the year ended December
